The drug-related Grade 3–4 AEs were neutropenia in 4 patients (23.5%), leukopenia in 2 (11.8%), and anemia, hypophosphatemia, prothrombin time-international normalized ratio (PT-INR) increased, pneumonitis, and acute myeloid leukemia in 1 patient (5.9%) each. This evidence concerns the gene F2 and hypophosphatemia.